| 摘要 |
The invention relates to isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH<SUB>2</SUB>; m is 0, 1 or 2; n is 1 or 2; R<SUB>1 </SUB>is H, when Y is NH<SUB>2</SUB>; or R. is H, (C<SUB>1-4</SUB>)alkyl or halogen, when Y is OH; R<SUB>2 </SUB>and R<SUB>3 </SUB>are independently H, (C<SUB>1-4</SUB>)alkyl or halogen; R is H or (C<SUB>1-6</SUB>)alkyl, optionally substituted with OH, (C<SUB>1-4</SUB>)-alkyloxy, (C<SUB>1-4</SUB>)alkyloxycarbonyl, (C<SUB>3-7</SUB>)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C<SUB>6-10</SUB>)aryl, (C<SUB>6-10</SUB>)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C<SUB>1-4</SUB>)alkyl, (C<SUB>1-4</SUB>)alkyloxy, (C<SUB>1-4</SUB>)alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.
|
